ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010
Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans.Neuroscience and biobehavioral reviews · 2018Pooled it
- Effect of varenicline on aspects of inhibitory control in smokers.Psychopharmacology · 2014Trial
- Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.Neurology · 2012Trial
- The physiological effects of APOE genotype in healthy young/middle-aged individuals.Biological reviews of the Cambridge Philosophical Society · 2026Article
- Perceptual discrimination of complex objects: Apolipoprotein E e4 gene-dose effects in mid-life.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Impact ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Interactions between physical exercise, associative memory, and genetic risk for Alzheimer's disease.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Impact of genetic predisposition to late-onset neurodegenerative diseases on early life outcomes and brain structure.Translational psychiatry · 2024Review
- Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort.GeroScience · 2024Article
- Dissociable effects ofNature aging · 2021Article
- Experimental and real-world evidence supporting the computational repurposing of bumetanide forNature aging · 2021Article
- APOE genotype influences P3b amplitude and response to smoking abstinence in young adults.Psychopharmacology · 2021Article
- APOE modifies the interaction of entorhinal cerebral blood flow and cortical thickness on memory function in cognitively normal older adults.NeuroImage · 2019Article
- The Effects of Nicotine and Tobacco Use on Brain Reward Function: Interaction With Nicotine Dependence Severity.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Article
- Review
- Putative Survival Advantages in Young Apolipoprotein ɛ4 Carriers are Associated with Increased Neural Stress.Journal of Alzheimer's disease : JAD · 2019Review
- Dissociable effects of the apolipoprotein-E (APOE) gene on short- and long-term memories.Neurobiology of aging · 2019Article
- Using event-related fMRI to examine sustained attention processes and effects of APOE ε4 in young adults.PloS one · 2018Article
- Nicotine increases anterior insula activation to expected and unexpected outcomes among nonsmokers.Psychopharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of putative cognitive-enhancing compounds to improve mental processing both in healthy and vulnerable populations is an area of growing interest to scientific and clinical communities. The possible influence of individual genetic differences on efficacy of these compounds has yet to be considered. We sought to investigate the profile of young-adult apolipoprotein E (APOE) varepsilon4 carriers across cognitive domains given that possession of this gene variant increases risk of developing dementia in later life. We also explored whether APOE genotype interacts with the cognitive enhancer, nicotine. A total of 1 mg of the cholinergic agonist nicotine was administered through nasal spray to healthy non-smoking young adults (aged 18-30) with either varepsilon3/varepsilon3 (N=29) or varepsilon4 (at least one varepsilon4 allele, N=27) genotype. Participants were matched on age, sex, and IQ in a placebo-controlled, double-blind 2 (drug: placebo, nicotine) x 2 (genotype: varepsilon3, varepsilon4) between subjects design. Here, we show that, paradoxically, possession of the varepsilon4 allele confers a cognitive advantage on tasks mediated by the frontal lobe, and that young carriers of the varepsilon4 allele show larger cognitive benefit from procholinergic nicotinic stimulation. These results are the first to show that genetic differences influence the efficacy of a cognitive enhancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.